Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seer, Inc. - Class A Common Stock (NQ:SEER)

2.090 +0.030 (+1.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 130,670
Open 2.050
Bid (Size) 1.990 (2,100)
Ask (Size) 2.100 (2,500)
Prev. Close 2.060
Today's Range 2.040 - 2.110
52wk Range 1.620 - 2.410
Shares Outstanding 61,423,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Radoff-JEC Group Issues Open Letter to Seer Inc.’s Board of Directors Regarding the Immediate Need for Significant Change
From On Behalf of The Radoff-JEC Group
Via Business Wire
News headline image
Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights 
From Seer, Inc.
Via GlobeNewswire

Performance

YTD
+14.8%
+14.8%
1 Month
+7.7%
+7.7%
3 Month
+8.3%
+8.3%
6 Month
+0.5%
+0.5%
1 Year
-6.3%
-6.3%

More News

Read More
News headline image
Seer to Participate in the TD Cowen 46th Annual Health Care Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Seer, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025
From Seer, Inc.
Via GlobeNewswire
News headline image
SEER INC (NASDAQ:SEER) Reports Q3 2025 Results with Narrow Revenue Beat and Reduced Losses ↗
Via Chartmill
News headline image
Seer Reports Third Quarter 2025 Financial Results
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in Upcoming November Investor Conferences
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
From Seer, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Appoints Isaac Ro to its Board of Directors
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer (SEER) Q2 Revenue Jumps 32% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Seer (SEER) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report Second Quarter 2025 Financial Results on August 6, 2025
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
From Seer, Inc.
Via GlobeNewswire
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
From Seer, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Seer, Inc. - Class A Common Stock publicly traded?
Yes, Seer, Inc. - Class A Common Stock is publicly traded.
What exchange does Seer, Inc. - Class A Common Stock trade on?
Seer, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Seer, Inc. - Class A Common Stock?
The ticker symbol for Seer, Inc. - Class A Common Stock is SEER on the Nasdaq Stock Market
What is the current price of Seer, Inc. - Class A Common Stock?
The current price of Seer, Inc. - Class A Common Stock is 2.090
When was Seer, Inc. - Class A Common Stock last traded?
The last trade of Seer, Inc. - Class A Common Stock was at 02/24/26 04:00 PM ET
What is the market capitalization of Seer, Inc. - Class A Common Stock?
The market capitalization of Seer, Inc. - Class A Common Stock is 128.37M
How many shares of Seer, Inc. - Class A Common Stock are outstanding?
Seer, Inc. - Class A Common Stock has 128M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.